Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
BlackRock, Inc. reports beneficial ownership of 4,879,068 shares of ANTERIS TECHNOLOGIES GLOBAL CORP common stock, representing 5.01% of the class as of 03/31/2026. The filing lists sole voting power for 4,810,606 shares and sole dispositive power for 4,879,068 shares. The Schedule 13G was signed by Spencer Fleming on 04/27/2026 and notes holdings reflect securities held by certain Reporting Business Units of BlackRock.
Anteris Technologies Global Corp. files a prospectus supplement updating its Registration Statement to cover the resale of up to 9,103,796 shares of Common Stock by the selling stockholders named in the Prospectus. The supplement attaches a Form 8-K reporting a new lease.
The Form 8-K discloses a lease through a wholly owned subsidiary for approximately 181,436 square feet in Brooklyn Park, Minnesota, with an initial term from September 1, 2026 to August 31, 2037. The lease specifies an initial monthly minimum rent of $152,708.63, contractual rent abatements (first three months fully abated, succeeding nine months partially abated), annual escalations, and payment of taxes and operating expenses. The lease description is qualified by the full lease to be filed as an exhibit to the Company’s Form 10-Q.
Anteris Technologies Global Corp. has entered into a long-term lease for approximately 181,436 square feet of office and warehouse space in Brooklyn Park, Minnesota, through its wholly owned subsidiary Anteris Technologies Corporation.
The lease starts on September 1, 2026 and runs through August 31, 2037, with options to extend for two additional 84‑month periods at market rent. Initial monthly minimum rent is $152,708.63, subject to contractual abatements, annual escalations and other adjustments, plus real estate taxes, operating expenses and other charges. Rent is fully abated for the first three months and partially abated for the following nine months, which eases cash outlay during the initial occupancy period.
Anteris Technologies Global Corp. registers 9,103,796 shares for resale by selling stockholders. The registration covers up to 9,103,796 shares of Common Stock, comprised of 2,346,936 Shares, 2,346,936 Common Stock Warrant Shares, 2,079,962 CDI Shares and 2,329,962 CDI Warrant Shares.
The prospectus states the Company will not receive proceeds from secondary resales but may receive up to $40.4 million in aggregate gross proceeds if the Warrants are exercised. The filing describes the 2025 Private Placement, the 2026 Public Offering and the Medtronic private placement, and includes selling stockholder tables and plan of distribution methods.
Anteris Technologies Global Corp. is registering the resale of 9,103,796 shares of Common Stock pursuant to a post-effective amendment to its Form S-1.
The registration covers (i) 2,346,936 Shares, (ii) 2,346,936 Common Stock Warrant Shares, (iii) 2,079,962 CDI Shares, and (iv) 2,329,962 CDI Warrant Shares. The Company states it will not receive proceeds from resale by the selling stockholders, but may receive up to $40.4 million in aggregate gross proceeds upon exercise of the Warrants. Shares outstanding were 36,062,370 as of September 30, 2025.
This Post-Effective Amendment No. 1 incorporates by reference the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and confirms no additional securities are being registered in this amendment.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported an equity award in the form of 78,740 Restricted Stock Units (RSUs) on March 4, 2026. The RSUs were acquired as a grant at a price of $0.0000 per unit, increasing his direct derivative holdings to 78,740 RSUs.
Each RSU represents a right to receive one CHESS Depositary Interest (CDI), and each CDI represents an interest in one share of Anteris common stock. The RSUs vest in three approximately equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, subject to McDonnell’s continued service through each vesting date.
Anteris Technologies Global Corp. disclosed that its Compensation Committee approved a one-time, discretionary grant of restricted stock units (RSUs) to Chief Financial Officer Matthew McDonnell. The award has a target value of $500,000, with the exact number of RSUs set by the closing price of the Company’s common stock on March 4, 2026, the grant date.
One-third of the RSUs will vest on each of the first three anniversaries of the grant date, contingent on Mr. McDonnell’s continued employment. The RSUs fully vest earlier if he dies, becomes permanently disabled, or experiences certain terminations in connection with a change in control. Once vested, the RSUs will be settled in CHESS depositary interests of the Company and are described as a special award that does not change his 2026 annual equity target.
Anteris Technologies Global Corp. reported weaker 2025 financial results alongside a strategic update on its DurAVR® transcatheter heart valve program. Revenue from ordinary activities was US$1.9 million in 2025, down from US$2.7 million in 2024, a 29% decline as the company focused on clinical development.
The loss from ordinary activities after tax increased to US$94.2 million from US$76.0 million, and loss attributable to members rose to US$94.1 million. Net tangible asset backing per share deteriorated from US$1.74 to (US$0.01) as of December 31, 2025, reflecting accumulated losses. Net operating cash outflows were US$77.8 million, in line with higher clinical, regulatory and manufacturing spend to support its pivotal Trial. The company confirmed that all US$80.0 million of net IPO proceeds raised in December 2024 have been fully used, paid no dividends, and saw no material impact from deregistering two Australian subsidiaries. The Trial has begun enrolling and implanting patients, targeting about 1,000 participants in a head‑to‑head study versus existing TAVR valves.
Anteris Technologies Global Corp. files its annual report describing a development-stage structural heart company focused on the DurAVR® transcatheter heart valve (THV) system for aortic stenosis. DurAVR® combines a single-piece biomimetic valve made from proprietary ADAPT® anti-calcification tissue with the ComASUR® balloon-expandable delivery system.
More than 130 patients have received DurAVR® worldwide through first-in-human, early feasibility and compassionate-use cases, showing favorable hemodynamics and high technical success in small aortic annuli. In 2025, Anteris began a global randomized pivotal Trial comparing DurAVR® to approved TAVR devices, enrolling first patients in Denmark after European approval and securing a staged FDA IDE for the first 200 U.S. patients.
The company targets a growing TAVR market that FMI estimates could reach $9.9 billion for severe aortic stenosis and $2.5 billion for valve-in-valve procedures by 2028, with North America and Europe as core regions. Anteris remains loss-making, relies on single-source suppliers and development partners, holds 47 active patents and 75 pending applications as of December 31, 2025, and faces extensive clinical, regulatory, financing and competitive risks highlighted in its risk factor summary.